14.2 BYDUREON BCISE Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus BYDUREON BCISE versus BYETTA, Both as Monotherapy or as Add-on to Metformin, a Sulfonylurea, a Thiazolidinedione, or Combination of Oral Agents A 28-week, randomized, open-label comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON BCISE to BYETTA in adult patients with type 2 diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or a combination of any two of these therapies (Trial 1 - NCT01652716)
Additionally, the anti-inflammatory properties of this peptide protocol can be especially valuable for individuals dealing with chronic conditions
Healthy lifestyle is the key
Acsl4 deletion attenuated renal impairment and oxidative stress in the oxalate-induced AKI mouse model To clarify the significance of ferroptosis in oxalate-induced AKI, we first generated a mouse model with renal tubule-specific deletion of ACSL4 ( Acsl4 fl/fl Ksp Cre-ERT2 ) (Fig
As always, because detoxification can temporarily shift how you feel and interact with other treatments, it is crucial to consult with a healthcare provider who understands the nuances of complex chronic illness before starting any new supplement regimen